I. Company Overview
Shanghai Xuantai Haimen Pharmaceutical Co., Ltd. was formerly Shanghai Qinyi Nantong Pharmaceutical Co., Ltd., which was wholly acquired by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. on October 30, 2014 and renamed Shanghai Xuantai Haimen Pharmaceutical Co., Ltd., with a registered capital of RMB 94.752 million and an estimated total investment of over RMB 500 million. The company is a pharmaceutical enterprise mainly producing solid preparations such as tablets, hard capsules, and granules.
The company covers an area of about 83 mu, with a total construction area of 17,000 square meters. The company's management team and key technical members mainly come from the Shanghai headquarters and consist of senior well-known experts with extensive industry experience. The main R&D backbone all have more than 15 years of management experience and professional R&D experience in large multinational pharmaceutical companies, and have participated in and led the R&D of various pharmaceutical technologies and formulation products and successfully launched them in European and American countries, with rich practical experience in high-end generic drugs, project management, and modern enterprise management.
Shanghai Xuantai Pharmaceutical Technology Co., Ltd. was established in August 2012, with a registered capital of RMB 100 million, an initial investment of RMB 230 million, and an additional investment of RMB 150 million. Located in Zhangjiang, Shanghai, known as China's Pharma Valley, the company is a high-tech enterprise mainly engaged in the R&D, innovation, industrial production, and sales of high-end pharmaceutical formulation technologies and products. Its establishment received strong support from the Shanghai Municipal Government and the Shanghai Advanced Research Institute of the Chinese Academy of Sciences. It has successively jointly established the "New Drug Creation Laboratory" R&D center with the Advanced Research Institute, its important manufacturing center, its wholly-owned subsidiary ---- Shanghai Xuantai Haimen Pharmaceutical Co., Ltd., and its wholly-owned commercial subsidiary ---- Shanghai Xuantai Biotechnology Co., Ltd., forming a full industry chain pattern of pharmaceutical production.
II. Project Overview
Shanghai Xuantai Haimen Pharmaceutical Co., Ltd., as the main manufacturing base for pharmaceutical preparations of Xuantai, will mainly carry out the production of process scale-up batches, validation batches, and marketing registration batches of R&D products as well as domestic and international commercial production, and has high industry strength in products, production, technology, management, capital, and professionals.
After completing the acquisition and restructuring, the company successfully completed the certification of China's new version of GMP on March 9, 2015, and smoothly launched the production and sales of domestic products. Daily operations have been managed in strict accordance with high-level GMP standards and advanced concepts. Xuantai possesses and masters internationally advanced formulation technologies, such as the solubilization technology platform for poorly soluble drugs, the sustained and controlled release pharmaceutical formulation technology platform, and the stability formulation technology platform for unstable drugs, and is good at effectively applying these technologies, selecting suitable major and special drugs and carrying out formulation improvement and innovation targeting their shortcomings, completing relevant technical feasibility and bioequivalence experiments, and realizing industrial production, which is exactly the core technology and competitiveness of our Xuantai. At the same time, with the upgrading of pharmaceutical consumption, the use of new formulations has become an inevitable trend, and Shanghai Xuantai is focusing on the international market. Since 2015, the company has prepared to launch the "International Certification Renovation Project for Solid Preparation Workshop", carrying out comprehensive international-standard workshop upgrading and expansion of the existing solid preparation workshop, and has successively introduced and equipped multiple internationally and domestically first-class pharmaceutical formulation production line equipment. As of the end of 2017, the total investment in instruments and equipment reached about RMB 40 million, and the total investment in instruments and equipment from 2016 to 2020 is expected to exceed RMB 50 million; at the same time, it has established and improved the relevant international cGMP quality management system and passed the USFDA pharmaceutical formulation certification on September 16, 2016. Guided by national policies, the company is committed to developing and producing reliable drugs with international standards and quality levels, so that more domestic and foreign patients can benefit, and contributing its own strength to the development of medicine in China and the world.
III. Project Progress
At present, the implementation of the company's "International Certification Renovation Project for Solid Preparation Workshop" has been completed in stages, the workshop renovation has been fully completed and put into use, the core technical hardware equipment has basically been equipped in place, and the commissioning and validation work has been completed, some equipment has been smoothly put into production, and at the same time a professional cGMP quality management system has been formed to standardize quality assurance in the drug production process. After the completion of the project renovation, from September 2015 to December 2017, 10 projects have completed ANDA registration batch applications.
IV. Development Ideas for the 13th Five-Year Plan
(1) The company's short-term goals (within 2016-2017, foundation building period):
(a) International-standard workshop renovation and expansion
(b) Improving the construction of a professional talent team and a high-level quality management system
(c) Cooperating with the company's R&D department to complete domestic and international registration batch production
(d) Accepting commissioned R&D and filing processing business.
The company's medium-term goals (2018-2019, product accumulation period):
(a) Welcome and officially pass US FDA and EU international certification
(b) New products launched, 4-5 products successfully registered for international production and starting commercial production
(c) Gradual establishment of domestic self-operated teams and construction of overseas sales networks, striving for the company to achieve profitability in 2018
(d) Construction and improvement of a company operating model with Xuantai characteristics.
The company's long-term goals (2019-2020, development breakthrough period):
(a) Complete the production registration of 15-20 domestic and foreign products, and complete marketing approval for 5-10 products
(b) Rapid expansion of domestic and foreign sales business, comprehensive growth of international business, and rapid scaling of turnover
(c) In 2021, the company's sales will exceed USD 50 million, with net profit of no less than USD 10 million
(d) Xuantai's business model can be replicated.
What does Jiangsu Xuantai Pharmaceutical Co., Ltd. require? Who is Jiangsu Xuantai Pharmaceutical Co., Ltd. hiring? recruitment: 工厂生产类占比最多占41.7%,其次是其他(研发和技术类)占16.7%. What education can get in at ? 大专占比最多占83.3%,其次是本科占16.7%. Work experience required at ? 不限占比最多占58.3%,其次是1-3年占41.7%. Where are the job locations at ? 南通占比最多占91.7%,其次是嘉兴占8.3%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows